Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:HALO
- CUSIP: 40637H10
- Web: www.halozyme.com
Capitalization:- Market Cap: $1.68595 billion
- Outstanding Shares: 134,013,000
Average Prices:- 50 Day Moving Avg: $12.82
- 200 Day Moving Avg: $13.13
- 52 Week Range: $8.18 - $15.20
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -14.49
- P/E Growth: -0.22
Sales & Book Value:- Annual Revenue: $134.17 million
- Price / Sales: 11.87
- Book Value: $0.43 per share
- Price / Book: 27.63
Profitability:- EBIDTA: ($95,850,000.00)
- Net Margins: -89.43%
- Return on Assets: -43.03%
Debt:- Debt-to-Equity Ratio: 2.85%
- Current Ratio: 4.13%
- Quick Ratio: 3.94%
Misc:- Average Volume: 1.14 million shs.
- Beta: 2.19
- Short Ratio: 33.39
Frequently Asked Questions for Halozyme Therapeutics (NASDAQ:HALO)
What is Halozyme Therapeutics' stock symbol?
Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."
How were Halozyme Therapeutics' earnings last quarter?
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. The business earned $33.80 million during the quarter, compared to analysts' expectations of $31.76 million. The business's revenue was up 1.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.21) EPS. View Halozyme Therapeutics' Earnings History.
Where is Halozyme Therapeutics' stock going? Where will Halozyme Therapeutics' stock price be in 2017?
8 brokers have issued 12-month target prices for Halozyme Therapeutics' shares. Their forecasts range from $7.00 to $20.00. On average, they anticipate Halozyme Therapeutics' stock price to reach $14.86 in the next year. View Analyst Ratings for Halozyme Therapeutics.
Who are some of Halozyme Therapeutics' key competitors?
Some companies that are related to Halozyme Therapeutics include AveXis (AVXS), Juno Therapeutics (JUNO), Agios Pharmaceuticals (AGIO), BeiGene (BGNE), Intercept Pharmaceuticals (ICPT), GW Pharmaceuticals PLC (GWPH), China Biologic Products (CBPO), Ultragenyx Pharmaceutical (RARE), Sarepta Therapeutics (SRPT), Spark Therapeutics (ONCE), Axovant Sciences (AXON), Prothena Corporation PLC (PRTA), Aerie Pharmaceuticals (AERI), Loxo Oncology (LOXO), NovoCure Limited (NVCR), Radius Health (RDUS), Array BioPharma (ARRY) and Lexicon Pharmaceuticals (LXRX).
Who are Halozyme Therapeutics' key executives?
Halozyme Therapeutics' management team includes the folowing people:
- Connie L. Matsui, Chairman of the Board
- Helen I Torley, President, Chief Executive Officer, Director
- Laurie D. Stelzer, Chief Financial Officer, Senior Vice President
- Mark J. Gergen J.D., Chief Operating Officer, Senior Vice President
- Harry J. Leonhardt Esq., Senior Vice President, Chief Compliance Officer, General Counsel
- Athena M. Countouriotis M.D., Senior Vice President, Chief Medical Officer
- Jean-Pierre Bizzari M.D., Independent Director
- James M. Daly, Independent Director
- Jeffrey William Henderson, Independent Director
- Kenneth J. Kelley, Independent Director
Who owns Halozyme Therapeutics stock?
Halozyme Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Third Security LLC (15.03%),
KIRK RANDAL J
(12.40%), BlackRock Inc. (9.02%), Iridian Asset Management LLC CT (8.25%), Vanguard Group Inc. (7.46%) and BB Biotech AG (6.43%). View Institutional Ownership Trends for Halozyme Therapeutics.
Who sold Halozyme Therapeutics stock? Who is selling Halozyme Therapeutics stock?
Halozyme Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, FMR LLC, Ameriprise Financial Inc., JPMorgan Chase & Co., Kennedy Capital Management Inc., LLBH Private Wealth Management LLC, IFC Holdings Incorporated FL and Artisan Partners Limited Partnership. View Insider Buying and Selling for Halozyme Therapeutics.
Who bought Halozyme Therapeutics stock? Who is buying Halozyme Therapeutics stock?
Halozyme Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including The Manufacturers Life Insurance Company , Vanguard Group Inc., Senzar Asset Management LLC, Granite Investment Partners LLC, BlackRock Inc., BB Biotech AG, Rubric Capital Management LP and Iridian Asset Management LLC CT. View Insider Buying and Selling for Halozyme Therapeutics.
How do I buy Halozyme Therapeutics stock?
Shares of Halozyme Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Halozyme Therapeutics' stock price today?
One share of Halozyme Therapeutics stock can currently be purchased for approximately $11.88.
MarketBeat Community Rating for Halozyme Therapeutics (NASDAQ HALO)MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Halozyme Therapeutics (NASDAQ:HALO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 2 Hold Ratings, 5 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $14.86 (25.06% upside) |
Analysts' Ratings History for Halozyme Therapeutics (NASDAQ:HALO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/10/2017 | Piper Jaffray Companies | Set Price Target | Buy | $20.00 | High |  |
| 8/10/2017 | Jefferies Group LLC | Reiterated Rating | Underperform | $6.75 -> $7.00 | High | |
| 7/26/2017 | Canaccord Genuity | Set Price Target | Buy | $16.00 | High | |
| 6/23/2017 | Barclays PLC | Reiterated Rating | Overweight | $16.00 | Low | |
| 4/17/2017 | BMO Capital Markets | Initiated Coverage | Market Perform | $14.00 | Low | |
| 3/30/2017 | Deutsche Bank AG | Boost Price Target | Buy | $15.00 -> $17.00 | Low | |
| 1/6/2017 | Citigroup Inc. | Downgrade | Buy -> Neutral | | N/A | |
| 9/8/2016 | Wells Fargo & Company | Reiterated Rating | Buy | | N/A | |
| 3/9/2016 | JMP Securities | Lower Price Target | Market Outperform | $22.00 -> $20.00 | N/A | |
(Data available from 8/21/2015 forward)
Earnings History for Halozyme Therapeutics (NASDAQ:HALO)Earnings History by Quarter for Halozyme Therapeutics (NASDAQ HALO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/8/2017 | Q2 2017 | ($0.25) | ($0.23) | $31.76 million | $33.80 million | View | Listen | |
| 5/9/2017 | Q1 2017 | ($0.25) | ($0.26) | $30.79 million | $29.60 million | View | Listen | |
| 2/28/2017 | Q416 | ($0.30) | ($0.21) | $37.94 million | $39.00 million | View | Listen | |
| 11/7/2016 | Q316 | ($0.27) | ($0.23) | $34.43 million | $31.90 million | View | Listen | |
| 8/9/2016 | Q216 | ($0.27) | ($0.21) | $29.94 million | $33.30 million | View | N/A | |
| 5/9/2016 | Q116 | ($0.20) | ($0.16) | $29.65 million | $42.50 million | View | N/A | |
| 2/29/2016 | Q415 | ($0.08) | $0.03 | $37.06 million | $52.20 million | View | Listen | |
| 11/9/2015 | Q315 | ($0.16) | ($0.19) | $24.01 million | $20.80 million | View | N/A | |
| 8/10/2015 | Q215 | ($0.09) | $0.02 | $24.84 million | $43.40 million | View | Listen | |
| 5/11/2015 | Q115 | ($0.13) | ($0.12) | $19.40 million | $18.70 million | View | Listen | |
| 3/2/2015 | Q414 | ($0.07) | ($0.04) | $25.60 million | $30.38 million | View | N/A | |
| 11/10/2014 | Q314 | ($0.14) | ($0.16) | $16.50 million | $14.60 million | View | N/A | |
| 8/11/2014 | Q214 | ($0.18) | ($0.13) | $13.71 million | $18.40 million | View | N/A | |
| 5/12/2014 | Q114 | ($0.14) | ($0.22) | $13.37 million | $12.00 million | View | N/A | |
| 2/27/2014 | Q413 | ($0.17) | ($0.19) | $21.80 million | $12.50 million | View | N/A | |
| 11/8/2013 | Q313 | ($0.15) | ($0.17) | $14.62 million | $16.00 million | View | N/A | |
| 8/7/2013 | Q2 2013 | ($0.13) | ($0.13) | $11.29 million | $14.50 million | View | N/A | |
| 5/8/2013 | Q1 2013 | ($0.15) | ($0.17) | $7.05 million | $11.83 million | View | N/A | |
| 2/25/2013 | Q4 2012 | ($0.16) | ($0.04) | $7.32 million | $21.80 million | View | N/A | |
| 11/8/2012 | Q312 | ($0.13) | ($0.18) | $6.09 million | $5.33 million | View | N/A | |
| 8/6/2012 | | ($0.15) | ($0.13) | | | View | N/A | |
| 5/7/2012 | | ($0.11) | $0.14 | | | View | N/A | |
| 3/9/2012 | | ($0.16) | ($0.18) | | | View | N/A | |
| 11/7/2011 | | ($0.03) | $0.05 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Halozyme Therapeutics (NASDAQ:HALO)2017 EPS Consensus Estimate: ($1.07)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.27) | ($0.27) | ($0.27) |
| Q2 2017 | 1 | ($0.27) | ($0.27) | ($0.27) |
| Q3 2017 | 1 | ($0.27) | ($0.27) | ($0.27) |
| Q4 2017 | 1 | ($0.26) | ($0.26) | ($0.26) |
(Data provided by Zacks Investment Research)
Dividend History for Halozyme Therapeutics (NASDAQ:HALO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Halozyme Therapeutics (NASDAQ:HALO)Insider Ownership Percentage: 16.80%
Institutional Ownership Percentage: 81.09%
Insider Trades by Quarter for Halozyme Therapeutics (NASDAQ:HALO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/20/2015 | Laurie Stelzer | CFO | Buy | 10,000 | $17.24 | $172,400.00 | |
| 6/18/2015 | Kenneth J Kelley | Director | Sell | 20,000 | $21.00 | $420,000.00 | |
| 9/16/2014 | David A Ramsay | CFO | Buy | 25,000 | $8.90 | $222,500.00 | |
| 9/16/2014 | Helen Torley | CEO | Buy | 50,000 | $8.92 | $446,000.00 | |
| 8/19/2014 | John Stuart Patton | Director | Sell | 75,000 | $9.96 | $747,000.00 | |
| 5/15/2014 | Robert Engler | Director | Sell | 126,700 | $7.56 | $957,852.00 | |
| 9/16/2013 | John Stuart Patton | Director | Sell | 75,000 | $9.13 | $684,750.00 | |
| 8/19/2013 | H. Michael Shepard | VP | Sell | 10,000 | $7.11 | $71,100.00 | |
| 8/14/2013 | Kathryn Falberg | Director | Buy | 100,000 | $6.82 | $682,000.00 | |
| 11/29/2012 | Robert Engler | Director | Buy | 15,000 | $5.57 | $83,550.00 | |
| 11/14/2012 | James P Shaffer | VP | Buy | 20,000 | $5.22 | $104,400.00 | |
| 11/13/2012 | Kathryn E Falberg | Director | Buy | 50,000 | $5.21 | $260,500.00 | |
| 8/27/2012 | Kenneth J Kelley | Director | Buy | 20,000 | $5.70 | $114,000.00 | |
| 8/13/2012 | Gregory Ian Frost | CEO | Buy | 2,000 | $5.50 | $11,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Halozyme Therapeutics (NASDAQ:HALO)
Latest Headlines for Halozyme Therapeutics (NASDAQ:HALO)
| Source: |
|
| Date | Headline |
|---|
 | Halozyme Therapeutics, Inc. (HALO) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - August 19 at 11:06 AM |
| Halozyme Therapeutics, Inc. (NASDAQ:HALO) Upgraded at Zacks Investment Research
www.americanbankingnews.com - August 11 at 10:58 PM |
 | See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
finance.yahoo.com - August 11 at 7:46 PM |
| Jefferies Group Comments on Halozyme Therapeutics, Inc.'s Q3 2017 Earnings (HALO)
www.americanbankingnews.com - August 11 at 8:56 AM |
| Halozyme Therapeutics, Inc. (HALO) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - August 10 at 12:47 PM |
| Edited Transcript of HALO earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 5:36 AM |
| Halozyme Therapeutics, Inc. (HALO) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - August 9 at 10:05 PM |
 | Halozyme Reports Second Quarter 2017 Results - PR Newswire (press release)
www.prnewswire.com - August 9 at 7:30 PM |
 | BRIEF-Halozyme reports Q2 loss per share $0.23
www.reuters.com - August 9 at 12:05 AM |
| Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : August 8, 2017
finance.yahoo.com - August 9 at 12:05 AM |
| Halozyme Reports Second Quarter 2017 Results
finance.yahoo.com - August 8 at 7:01 PM |
| Halozyme Therapeutics reports 2Q loss
finance.yahoo.com - August 8 at 7:01 PM |
| Halozyme Therapeutics, Inc. (NASDAQ:HALO) Expected to Announce Quarterly Sales of $33.11 Million
www.americanbankingnews.com - August 7 at 9:06 AM |
| Zacks: Analysts Anticipate Halozyme Therapeutics, Inc. (NASDAQ:HALO) to Post -$0.25 Earnings Per Share
www.americanbankingnews.com - August 5 at 10:24 AM |
| Halozyme Therapeutics To Present At Upcoming Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - August 4 at 7:36 PM |
| Halozyme Therapeutics To Present At Upcoming Healthcare Conference
finance.yahoo.com - August 4 at 7:36 PM |
| Halozyme Therapeutics, Inc. – Value Analysis (NASDAQ:HALO) : August 4, 2017
finance.yahoo.com - August 4 at 12:21 AM |
| Halozyme Therapeutics, Inc. (HALO) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 28 at 8:46 PM |
| Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : July 21, 2017
finance.yahoo.com - July 21 at 3:12 PM |
| Zacks: Analysts Anticipate Halozyme Therapeutics, Inc. (NASDAQ:HALO) Will Announce Quarterly Sales of $33.11 Million
www.americanbankingnews.com - July 16 at 10:48 AM |
| Initiation Of Clinical Trial Collaboration Evaluating Halozyme's PEGPH20 In Combination With Anti-PDL1 Immunotherapy - PR Newswire (press release)
www.prnewswire.com - July 14 at 8:56 PM |
| -$0.25 Earnings Per Share Expected for Halozyme Therapeutics, Inc. (NASDAQ:HALO) This Quarter
www.americanbankingnews.com - July 14 at 12:16 PM |
 | Halozyme Therapeutics (HALO) Announces Initiation Of Clinical ... - StreetInsider.com
www.streetinsider.com - July 13 at 3:57 PM |
| Initiation Of Clinical Trial Collaboration Evaluating Halozyme's PEGPH20 In Combination With Anti-PDL1 Immunotherapy
finance.yahoo.com - July 13 at 3:57 PM |
| Investor thought Martin Shkreli was like 'Rain Man' character because of his financial focus
finance.yahoo.com - July 11 at 12:23 AM |
| Halozyme To Host Second Quarter 2017 Financial Results Conference Call
finance.yahoo.com - July 10 at 7:22 PM |
| Investor thought Martin Shkreli was like 'Rain Man' character because of his financial focus
finance.yahoo.com - July 10 at 7:22 PM |
| Former Shkreli employee says 'pharma bro' was deeply depressed after hedge fund 'imploded'
finance.yahoo.com - July 8 at 11:17 AM |
| Martin Shkreli worker called him 'mentally unstable,' threatened to expose lies by 'scam artist'
finance.yahoo.com - July 8 at 11:17 AM |
| Former officer of Martin Shkreli hedge fund filed SEC complaint against Shkreli while at fund
finance.yahoo.com - July 8 at 11:17 AM |
| BRIEF-Halozyme Therapeutics, unit entered into first amendment to amended, restated lease with BMR-11388 ... - Reuters
www.reuters.com - July 7 at 6:02 AM |
| Martin Shkreli's lawyer and 'cowboy' venture capitalist duel over value of horses and investments
finance.yahoo.com - July 7 at 6:02 AM |
| Former Shkreli employee says 'pharma bro' was deeply depressed after hedge fund 'imploded'
finance.yahoo.com - July 7 at 6:02 AM |
| Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - July 3 at 6:32 PM |
| Halozyme Therapeutics, Inc. (NASDAQ:HALO) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - July 1 at 5:38 PM |
| Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : June 30, 2017
finance.yahoo.com - June 30 at 7:30 PM |
| Halozyme Phase 2 Data In Advanced Pancreas Cancer Presented ... - PR Newswire (press release)
www.prnewswire.com - June 28 at 11:54 PM |
| Halozyme Phase 2 Data In Advanced Pancreas Cancer Presented At European Society For Medical Oncology Symposium
finance.yahoo.com - June 28 at 6:54 PM |
| Dance Biopharm Appoints Steve Thornton to Board of Directors
www.prnewswire.com - June 27 at 5:48 PM |
| Halozyme FDA Action Date, Q1 Review, Analysts Outlook and Price Targets
finance.yahoo.com - June 26 at 7:23 PM |
| ETFs with exposure to Halozyme Therapeutics, Inc. : June 26, 2017
finance.yahoo.com - June 26 at 7:23 PM |
| Halozyme Therapeutics, Inc. (HALO) Lifted to Strong-Buy at BidaskClub
www.americanbankingnews.com - June 24 at 6:44 PM |
| FDA Approves Genentech's RITUXAN HYCELA, A Subcutaneous Rituximab Coformulated With Halozyme ENHANZE ... - PR Newswire (press release)
www.prnewswire.com - June 23 at 3:40 PM |
| Barclays PLC Reiterates "Overweight" Rating for Halozyme Therapeutics, Inc. (HALO)
www.americanbankingnews.com - June 23 at 9:32 AM |
| Halozyme (HALO) Pleased by FDA Approval of Genentech's RITUXAN HYCELA
www.streetinsider.com - June 23 at 2:58 AM |
| FDA Approves Genentech's RITUXAN HYCELA, A Subcutaneous Rituximab Coformulated With Halozyme ENHANZE Technology
finance.yahoo.com - June 23 at 2:58 AM |
| $33.11 Million in Sales Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter
www.americanbankingnews.com - June 22 at 12:42 PM |
| -$0.25 EPS Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter
www.americanbankingnews.com - June 20 at 8:07 AM |
| Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : June 19, 2017
finance.yahoo.com - June 19 at 12:40 PM |
| Halozyme Therapeutics, Inc. (HALO) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - June 16 at 10:34 PM |
Halozyme Therapeutics (HALO) Chart for Monday, August, 21, 2017
